G&E Healthcare Co Ltd
299480
Company Profile
Business description
G&E Healthcare Co Ltd, formerly G&E Biotech Co Ltd is a biopharmaceutical company focused on the development and commercialization of novel botanical extraction technology and products. It offers a range of products that include Hepato Protective Agent (Hepanamin) which prevent and cure for acute and chronic hepatitis, fatty liver conditions and liver toxicity infections, Botanical Healthcare product, and Botanical Anti-aging cosmetics.
Contact
No. 92, Keji 5th Road
Annan District
Tainan70955
TWNT: +886 63840890
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
10
Stocks News & Analysis
stocks
Short-term pain for long-term gain for undervalued ASX share
Cost reductions lower our profit estimates but should lead to improved long-term outcomes.
stocks
Qantas earnings: Jetstar capitalising on weaker domestic competition
Qantas’ budget brand performing well, with segment earnings up 55%.
stocks
Nvidia Earnings: No signs of a slowdown in demand for AI chips
A selloff in Nvidia stock on the earnings news looks like a buying opportunity to us.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,010.10 | 117.10 | -1.28% |
| CAC 40 | 7,719.71 | 65.46 | 0.86% |
| DAX 40 | 23,594.80 | 107.47 | 0.46% |
| Dow JONES (US) | 45,013.81 | 282.00 | -0.62% |
| FTSE 100 | 9,177.99 | 61.30 | 0.67% |
| HKSE | 25,343.43 | 153.12 | -0.60% |
| NASDAQ | 21,438.67 | 159.04 | 0.75% |
| Nikkei 225 | 41,938.89 | 371.60 | -0.88% |
| NZX 50 Index | 13,074.81 | 58.35 | -0.44% |
| S&P 500 | 6,423.74 | 8.20 | 0.13% |
| S&P/ASX 200 | 8,738.80 | 120.20 | -1.36% |
| SSE Composite Index | 3,813.56 | 44.58 | -1.16% |